Please provide your email address to receive an email when new articles are posted on . Daily tiotropium via the HandiHaler device improved lung function but did not reduce frequency of exacerbations ...

Using bronchodilators early on in patients with chronic obstructive pulmonary disease (COPD) is increasingly understood to be an important therapeutic intervention to improve quality of life, inhibit ...

Researchers from the University of Rochester identified improvement in pulmonary function in symptomatic adult patients with asthma treated with once-daily tiotropium. The following article is part of ...

Current data do not support increased risks for stroke, heart attack, or death The U.S. Food and Drug Administration today announced that data from a recent review of the Spiriva HandiHaler, a ...

Lupin has received the Food and Drug Administration’s permission for Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, which is a generic of Boehringer Ingelheim’s Spiriva HandiHaler. The ...

September 20, 2010 (Barcelona, Spain) — Adding the anticholinergic agent tiotropium bromide (Spiriva, Boehringer-Ingelheim and Pfizer), approved for the treatment of chronic obstructive pulmonary ...

The digital press release with multimedia content can be accessed here: Basel, May 21, 2014 - Novartis announced today new data from the QUANTIFY study, which ...

Dr Richard Russell, Consultant Chest Physician, Wexham Park Hospital and one of the UK study investigators said: "These results are promising for the many patients, who despite current treatment ...

In January 2004, tiotropium bromide (Spiriva; Boehringer Ingelheim/Pfizer), an orally inhaled anticholinergic drug, was approved by the US FDA for the treatment of chronic obstructive pulmonary ...

QUANTIFY study met primary endpoint demonstrating non-inferiority of Ultibro®Breezhaler® vs tiotropium 18 mcg plus formoterol 12 mcg in improving health-related quality of life outcomes[1],[2] ...